

119<sup>TH</sup> CONGRESS  
2<sup>D</sup> SESSION

# H. R. 9192

To amend the Employee Retirement Income Security Act of 1974, title XXVII of the Public Health Service Act, and the Internal Revenue Code of 1986 to require health insurance coverage of drugs indicated for the treatment of autoimmune diseases and certain blood disorders.

---

## IN THE HOUSE OF REPRESENTATIVES

JUNE 8, 2026

Ms. JOHNSON of Texas (for herself and Mr. LAWLER) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and Workforce, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

---

## A BILL

To amend the Employee Retirement Income Security Act of 1974, title XXVII of the Public Health Service Act, and the Internal Revenue Code of 1986 to require health insurance coverage of drugs indicated for the treatment of autoimmune diseases and certain blood disorders.

1        *Be it enacted by the Senate and House of Representa-*  
2        *tives of the United States of America in Congress assembled,*

3        **SECTION 1. SHORT TITLE.**

4        This Act may be cited as the “Prior Authorization  
5        Reform for Autoimmune and Blood Disorders Act”.

1 **SEC. 2. REQUIRING COVERAGE OF DRUGS INDICATED FOR**  
2 **THE TREATMENT OF AUTOIMMUNE DISEASES**  
3 **AND CERTAIN BLOOD DISORDERS.**

4 (a) ERISA AMENDMENTS.—

5 (1) IN GENERAL.—Subpart B of part 7 of sub-  
6 title B of title I of the Employee Retirement Income  
7 Security Act of 1974 (29 U.S.C. 1185 et seq.) is  
8 amended by adding at the end the following new sec-  
9 tion:

10 **“SEC. 727. REQUIREMENTS WITH RESPECT TO COVERAGE**  
11 **OF DRUGS FOR AUTOIMMUNE DISEASES AND**  
12 **CERTAIN BLOOD DISORDERS.**

13 “(a) IN GENERAL.—A group health plan, and a  
14 health insurance issuer offering group health insurance  
15 coverage—

16 “(1) shall provide coverage for any drug that is  
17 an autoimmune or blood disorder drug, without re-  
18 gard to whether such drug is dispensed by a phar-  
19 macy or furnished incident to another item or serv-  
20 ice for which benefits are available under such plan  
21 or coverage; and

22 “(2) may not require, with respect to an indi-  
23 vidual enrolled under such plan or coverage, that  
24 prior authorization for such a drug be obtained more  
25 than once during any 12-month period unless such  
26 drug is—

1           “(A) typically used for a period of 12  
2 months or less;

3           “(B) an opioid, a benzodiazepine, a bar-  
4 biturate, or carisoprodol; or

5           “(C) a drug with respect to which a risk  
6 evaluation and mitigation strategy is required  
7 under Section 505–1 of the Federal Food,  
8 Drug, and Cosmetic Act.

9           “(b) AUTOIMMUNE OR BLOOD DISORDER DRUG DE-  
10 FINED.—In this section, the term ‘autoimmune or blood  
11 disorder drug’ means a drug or biological product that is  
12 indicated and prescribed for the treatment of an auto-  
13 immune disease, hemophilia, or Von Willebrand disease.”.

14           (2) CLERICAL AMENDMENT.—The table of con-  
15 tents in section 1 of the Employee Retirement In-  
16 come Security Act of 1974 (29 U.S.C. 1001 et seq.)  
17 is amended by inserting after the item relating to  
18 section 726 the following:

“Sec. 727. Requirements with respect to coverage of drugs for autoimmune dis-  
eases and certain blood disorders.”.

19           (b) PUBLIC HEALTH SERVICE ACT AMENDMENTS.—  
20 Part D of title XXVII of the Public Health Service Act  
21 (42 U.S.C. 300gg–111 et seq.) is amended by adding at  
22 the end the following new section:

1 **“SEC. 2799A-12. REQUIREMENTS WITH RESPECT TO COV-**  
2 **ERAGE OF DRUGS FOR AUTOIMMUNE DIS-**  
3 **EASES AND CERTAIN BLOOD DISORDERS.**

4 “(a) IN GENERAL.—A group health plan, and a  
5 health insurance issuer offering group or individual health  
6 insurance coverage—

7 “(1) shall provide coverage for any drug that is  
8 an autoimmune or blood disorder drug, without re-  
9 gard to whether such drug is dispensed by a phar-  
10 macy or furnished incident to another item or serv-  
11 ice for which benefits are available under such plan  
12 or coverage; and

13 “(2) may not require, with respect to an indi-  
14 vidual enrolled under such plan or coverage, that  
15 prior authorization for such a drug be obtained more  
16 than once during any 12-month period unless such  
17 drug is—

18 “(A) typically used for a period of 12  
19 months or less;

20 “(B) an opioid, a benzodiazepine, a bar-  
21 biturate, or carisoprodol; or

22 “(C) a drug with respect to which a risk  
23 evaluation and mitigation strategy is required  
24 under Section 505-1 of the Federal Food,  
25 Drug, and Cosmetic Act.

1 “(b) AUTOIMMUNE OR BLOOD DISORDER DRUG DE-  
2 FINED.—In this section, the term ‘autoimmune or blood  
3 disorder drug’ means a drug or biological product that is  
4 indicated and prescribed for the treatment of an auto-  
5 immune disease, hemophilia, or Von Willebrand disease.”.

6 (c) INTERNAL REVENUE CODE AMENDMENTS.—

7 (1) IN GENERAL.—Subchapter B of chapter  
8 100 of the Internal Revenue Code of 1986 is amend-  
9 ed by adding at the end the following new section:

10 **“SEC. 9827. REQUIREMENTS WITH RESPECT TO COVERAGE**  
11 **OF DRUGS FOR AUTOIMMUNE DISEASES AND**  
12 **CERTAIN BLOOD DISORDERS.**

13 “(a) IN GENERAL.—A group health plan—

14 “(1) shall provide coverage for any drug that is  
15 an autoimmune or blood disorder drug, without re-  
16 gard to whether such drug is dispensed by a phar-  
17 macy or furnished incident to another item or serv-  
18 ice for which benefits are available under such plan;  
19 and

20 “(2) may not require, with respect to an indi-  
21 vidual enrolled under such plan, that prior author-  
22 ization for such a drug be obtained more than once  
23 during any 12-month period unless such drug is—

24 “(A) typically used for a period of 12  
25 months or less;

1           “(B) an opioid, a benzodiazepine, a bar-  
2           biturate, or carisoprodol; or

3           “(C) a drug with respect to which a risk  
4           evaluation and mitigation strategy is required  
5           under Section 505–1 of the Federal Food,  
6           Drug, and Cosmetic Act.

7           “(b) AUTOIMMUNE OR BLOOD DISORDER DRUG DE-  
8           FINED.—In this section, the term ‘autoimmune or blood  
9           disorder drug’ means a drug or biological product that is  
10          indicated and prescribed for the treatment of an auto-  
11          immune disease, hemophilia, or Von Willebrand disease.”.

12          (2) CLERICAL AMENDMENT.—The table of sec-  
13          tions for subchapter B of chapter 100 of the Inter-  
14          nal Revenue Code of 1986 is amended by adding at  
15          the end the following new item:

          “Sec. 9827. Requirements with respect to coverage of drugs for autoimmune  
          diseases and certain blood disorders.”.

16          (d) EFFECTIVE DATE.—The amendments made by  
17          this section shall apply with respect to plan years begin-  
18          ning on or after January 1, 2027.

○